Figitumumab (Anti-IGF1R / CD221)

製品コードA2942 別名: CP-751871 純度：99%

Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 58200	国内在庫あり
1mg*5	JPY 144600	お問い合わせ
1mg*25	JPY 432600	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る： A294201 純度： 99% タンパク質濃度： 5.223mg/ml 内毒素：＜1EU/mg

IGF-1R阻害剤の選択性比較

生物活性

製品説明	Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.

参考
https://pubmed.ncbi.nlm.nih.gov/24107449/

参考

https://pubmed.ncbi.nlm.nih.gov/24107449/

製品説明

CAS No.	943453-46-1
Molecular Weight	146
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06866548	ACTIVE_NOT_RECRUITING	Drug: anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb	mCRPC	Shanghai Changzheng Hospital	2025-03-10	EARLY_PHASE1
NCT06269393	COMPLETED	Drug: Placebo\|Drug: IBI311	Thyroid Associated Ophthalmopathy	Peking University People's Hospital	2024-01-01	PHASE3
NCT02916394	UNKNOWN		Molecular Imaging	Harbin Medical University	2018-09-01
NCT02546544	COMPLETED	Drug: Linsitinib	Relapsed Ewing Sarcoma; Refractory Ewing Sarcoma	University of Oxford	2014-03	PHASE2
NCT01008566	COMPLETED	Drug: Sorafenib Tosylate	Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma	National Cancer Institute (NCI)	2009-08	PHASE1
NCT01204476	COMPLETED	Drug: Everolimus\|Drug: Octreotide Acetate	Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Paraganglioma; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Merkel Cell Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor; Stage III Merkel Cell Carcinoma; Stage IV Merkel Cell Carcinoma; Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	2010-10	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-23)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須